Excess release of IL-33 may drive dysregulated hyper-inflammation in severe acute respiratory syndrome coronavirus 2 infection [19]; IL-33 levels are increased in patients with COVID-19 and are associated with disease severity [20]. Here, IL33 is linked to COVID-19.